Deviation Between Incidence Rates of Screenable Cancers and the Proportion of Late-Stage Disease
Journal of Surgical Research · 2026-10 · 326 · 1115-1123
DOI: 10.1016/j.jss.2026.07.044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Research, 2026-10. Verfasst von Anays Murillo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Boston Medical Center, Boston, Massachusetts; Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusett…. Hauptthemen laut MEDLINE: COVID-19, Colorectal Neoplasms, Early Detection of Cancer, Breast Neoplasms. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Health Resources and Services Administration.
Abstract (Originalsprache)
INTRODUCTION: Screening for cancer decreased during the COVID-19 pandemic, leading to fewer cancer cases and less than expected early-stage diagnoses. Due to this decrease, the subsequent literature suggested a tidal wave of increased incidence and a larger proportion of late-stage disease. METHODS: The National Cancer Database (NCDB) was used to identify screenable cancer cases from lung, female breast, and colorectal cancer from 2010 to 2023. These were standardized to calculate annual incidence rates per 100,000. A linear regression model of 2010-2022 incidence rates was used to calculate predicted incidence compared with observed incidence in 2023 (most recent NCDB data). Late-stage disease proportions (III/IV versus I/II) were also compared. Sensitivity analyses were conducted using alternative modeling periods and restricting to stable facility participation in NCDB. RESULTS: A total of 2,235,175 lung, 3,090,471 breast, and 1,448,861 colorectal cancer patients were analyzed. In 2023, the observed incidence was lower for lung 63.282 versus 68.914 (95% predictive interval 62.677-75.151), breast 174.055 versus 193.417 (95% PI 178.613-208.221), and colorectal 43.348 versus 45.517 (95% PI 41.266-49.769), although only breast was significantly lower. Observed and predicted late-stage disease proportions were similar for all three screenable cancers: lung: 56.0% versus 59.0%, breast: 11.6% versus 11.6%, and colorectal: 55.6% versus 56.8%. Findings were similar in sensitivity analyses. CONCLUSIONS: Despite the broadly accepted expectation that the incidence of screenable cancers would increase after the initial wave of the COVID-19 pandemic, the rates decreased, particularly for breast cancer. Furthermore, the expectation that late-stage cancers would rise significantly was not observed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Boston Medical Center, Boston, Massachusetts; Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
- Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
- Department of Surgery, Boston Medical Center, Boston, Massachusetts; Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts. Electronic address: Teviah.Sachs@bmc.org.
Förderung
- Health Resources and Services Administration
Zitieren
APA
Murillo, A., Myers, S., Romatoski, K. S., Ng, S. C., Kenzik, K., Tseng, J. F., Miller, C. P., & Sachs, T. E. (2026). Deviation Between Incidence Rates of Screenable Cancers and the Proportion of Late-Stage Disease. Journal of Surgical Research, 326, 1115-1123. https://doi.org/10.1016/j.jss.2026.07.044
Vancouver
Murillo A, Myers S, Romatoski KS, Ng SC, Kenzik K, Tseng JF, et al. Deviation Between Incidence Rates of Screenable Cancers and the Proportion of Late-Stage Disease. Journal of Surgical Research. 2026;326:1115-1123. doi:10.1016/j.jss.2026.07.044
BibTeX
@article{Murillo2026,
author = {Murillo, Anays and Myers, Sara and Romatoski, Kelsey S and Ng, Sing Chau and Kenzik, Kelly and Tseng, Jennifer F and Miller, Claire P and Sachs, Teviah E},
title = {Deviation Between Incidence Rates of Screenable Cancers and the Proportion of Late-Stage Disease},
journal = {Journal of Surgical Research},
year = {2026},
volume = {326},
pages = {1115--1123},
doi = {10.1016/j.jss.2026.07.044}
}
EUVIMED